Legend Biotech Stock News

Legend Bio's Carvykti has been approved and is selling well despite manufacturing issues. Analysts have set multibillion-dollar target peak sales for the product.

Legend Biotech's Carvykti was approved this year for the treatment of fourth and fifth-line-plus multiple myeloma. Carvykti is partnered with J&J, and the launch is off to a strong start despite suppl

The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on.

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-

Legend Biotech Corporation Sponsored ADR (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue mo

Investors, on second glance, might think the company's stock offering is a good idea.

BMO Capital Markets initiated coverage on Legend Biotech Corporation (NASDAQ: LEGN) with a price target of $77, and an Outperform rating. The analyst says the company's recently approved Carvykt

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-

The European Medicines Agency's CHMP recommended conditional approval of Janssen, a unit of Johnson & Johnson (NYSE: JNJ), and its partner Legend Biotech Corporation's (NASDAQ: LEGN) CAR-T thera

Analysts have provided the following ratings for Legend Biotech (NASDAQ: LEGN ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 1 0 0 0 These 4 analysts have an average price target of $56.25 versus the current price of Legend Biotech at $34.74, implying upside. Below is a summary of how these 4 analysts rated Legend Biotech over the past 3 months. The greater the number of … Full story available on Benzinga.com

In the last trading session, 1.31 million shares of the Legend Biotech Corporation (NASDAQ:LEGN) were traded. Most recently the company’s share price was $36.55, and it changed around $2.3 or 6.72% from the last close, which brings the market valuation of the company to $5.44B. LEGN currently trades at a discount to its 52-week high … Legend Biotech Corporation (NASDAQ: LEGN) Stock Forecast: $75.00 Per Share In 2022 With Positive Signs Read More »

The clinical-stage biopharmaceutical company, Legend Biotech (LEGN), announced on Monday an Interim Product Supply Agreement with Janssen Biotech of Johnson & Johnson (JNJ) for…

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB ) retreated in four out of five sessions of the week. Clinical trial updates and FDA-related news moved stocks, while earnings news flow tapered off. NuCana plc. (NASDAQ: NCNA ) was among the worst decliners of the week, with the stock reacting to the stalling of the company''s Phase 3 biliary tract cancer study. SAB Biotherapeutics, Inc. (NASDAQ: SABS ) shares also came under pressure after the National Institutes of Health pulled the plug on a Phase study of the company''s SAB-185 in COVID-19 patients. Celayad Oncology SA (NASDAQ: CYAD ) shares plunged after the company said it is pulling the plug on an early-stage biliary tract cancer study. FDA decisions scheduled for the week were mixed, with Amryt Pharma plc (NASDAQ: AMYT ) and Gilead Sciences, Inc. (NASDAQ: GILD ) failing to get their investigational drugs across the finish line.

Here''s why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.